Furthermore, we wanted to compare the combined treatment in B16F10 melanoma, which is a more immunogenic tumor, with a high expression of MCAM to TS/A carcinoma, which is a less immunogenic tumor with a low expression of MCAM. Here, MCAM is linked to neoplasm.